A PHASE 1B/3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY AND NIVOLUMAB VERSUS CHEMOTHERAPY AND NIVOLUMAB ALONE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE 102)
- Registry ID
- 20210098
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2023-03-17
- Last update
- 2022-02-10
Conditions
- GASTROESOPHAGEAL JUNCTION CANCER
Related clinical trials
- ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB
DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS
CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE
TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05)
- A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977)
- A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
- A RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE 101)
View on source registry